Axol Bioscience is proud to announce the expansion of its induced pluripotent stem cell (iPSC) line library, now featuring a diverse and comprehensive collection of patient-derived lines for ophthalmology research. This extended library includes iPSC lines from individuals diagnosed with age-related macular degeneration (AMD) and various forms of retinopathy, offering researchers unprecedented access to disease-relevant genetic backgrounds. These lines are available for use in the manufacture of retinal pigment epithelial (RPE) cells, a critical cell type for modeling dry AMD and advancing gene therapy development.
The newly expanded iPSC library supports Axol’s commitment to providing scalable, custom manufacturing of iPSC-derived cells. Researchers can choose to manufacture cells using Axol’s proprietary lines, their own lines, or third-party sources, with full onboarding and completion quality control to ensure reproducibility and performance. Axol’s RPE cells exhibit hallmark features such as pigmented, cobblestone morphology and high expression of key markers like MITF, ZO-1, and PMEL17, with purity exceeding 95% as confirmed by flow cytometry.
In addition to RPE cells, Axol offers iPSC-derived microglia, which are ideal for studying neuroinflammatory mechanisms in ophthalmology. These cells are assay-ready within seven days and express critical markers including IBA-1, TMEM119, and P2RY12. Their robust functional activity—measured through cytokine release, phagocytosis, and chemotaxis—makes them a powerful tool for co-culture systems and compound screening.
Axol’s service provision extends beyond cell manufacturing to include high-content and high-throughput compound testing platforms. Their dry AMD model replicates key disease mechanisms using chronic A2E treatment and blue light exposure to induce oxidative stress, inflammation, and RPE cell death. This model is available in both standard and miniaturized formats, enabling researchers to conduct scalable drug screening with multiple endpoints using automated liquid handling systems.
With this extended library and comprehensive service offering, Axol Bioscience continues to lead the way in supporting ophthalmology research and drug discovery. The company invites collaboration and co-development opportunities and encourages researchers to reach out to their dedicated ophthalmology team. For more information, visit axolbio.com or contact operations@axolbio.com.
